Oral mRNA Nanotherapy for Bleeding Disorder

口服 mRNA 纳米疗法治疗出血性疾病

基本信息

  • 批准号:
    10750040
  • 负责人:
  • 金额:
    $ 6.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-01 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Protein replacement therapy has been a cornerstone in treating genetic diseases (e.g., hemophilia) with loss or reduction of the function of a particular protein, by using recombinant proteins or recombinant engineered proteins. However, most protein therapeutics have short circulation lives, and thus require frequent invasive infusion to maintain their therapeutic efficacy. For example, the most common treatment for hemophilia A caused by a deficiency of blood clotting factor VIII (FVIII) is factor concentrate replacement, which is associated with burdensome frequent intravenous infusion. To address the unmet medical need of hemophilia, the major objective of this project is to develop a non-invasive oral mRNA delivery nanoplatform for durable protein replacement therapy requiring infrequent dosing. Synthetic mRNA has shown enormous potential for biomedical applications, with mRNA vaccines already clinically approved for COVID-19. Various delivery strategies have been developed to improve mRNA translation; however, an ongoing challenge of mRNA therapy is managing the transient efficacy due to its relatively short half-life, and oral mRNA delivery remains elusive. In my previous work, I have identified a unique poly(zwitterion)-lipid-based micelle platform that can cross the intestinal epithelial barrier and lead to a very potent oral bioavailability of biomolecules such as insulin. Recently, I have also discovered a new type of ionizable lipids that can extend the duration of mRNA-mediated protein expression. In this F32 project, I propose to combine the epithelium-crossing poly(zwitterion)-lipids and the unique ionizable lipids to develop an innovative mRNA delivery platform for oral, durable replacement therapy of bleeding disorders. In Aim 1, I will synthesize new poly(zwitterion)-lipids and ionizable lipids and generate a series of new mRNA lipid nanoparticles (LNPs), and systematically investigate their effects on oral transcytosis and the durability of protein expression in vitro and in vivo. In Aim 2, we will select the top-performing LNPs for oral delivery of FVIII mRNA and evaluate the FVIII mRNA nanotherapy in healthy and hemophilia mouse models. With the successful completion of this project, we expect that the oral durable mRNA delivery strategy will provide a more effective and robust therapy for hemophilia and other bleeding disorders.
摘要 蛋白质替代疗法已经成为治疗遗传疾病(例如,血友病), 通过使用重组蛋白质或重组工程化的蛋白质来降低特定蛋白质的功能 proteins.然而,大多数蛋白质治疗剂具有短的循环寿命,因此需要频繁的侵入性治疗。 输注以维持其治疗功效。例如,血友病A最常见的治疗方法是 凝血因子VIII(FVIII)缺乏是因子浓缩物替代,这与 频繁静脉输液的负担为了解决血友病未得到满足的医疗需求, 本项目的目的是开发一种非侵入性的口服mRNA递送纳米平台,用于持久的蛋白质 需要不频繁给药的替代疗法。人工合成的mRNA在生物医学领域显示出巨大的潜力。 mRNA疫苗已经获得临床批准用于COVID-19。各种交付战略 已经开发了改善mRNA翻译;然而,mRNA治疗的持续挑战是管理 由于其相对短的半衰期和口服mRNA递送而产生的瞬时功效仍然难以捉摸。在我以前的 工作,我已经确定了一个独特的聚(zwitzerland)-脂质为基础的胶束平台,可以通过肠上皮细胞 屏障并导致生物分子如胰岛素的非常有效的口服生物利用度。最近,我也 发现了一种新型的可电离脂质,可以延长mRNA介导的蛋白质表达的持续时间。在 这个F32项目,我建议将联合收割机结合上皮交叉聚(两性)脂质和独特的可电离的 脂质开发一种创新的mRNA递送平台,用于口服,持久的出血替代疗法 紊乱目的一是合成新型聚两性离子脂质和可离子化脂质, mRNA脂质纳米粒(LNPs),并系统地研究其对口腔转胞吞作用和细胞增殖的影响。 体外和体内蛋白表达的持久性。在目标2中,我们将选择表现最好的LNP用于口服 在健康和血友病小鼠模型中递送FVIII mRNA并评估FVIII mRNA纳米疗法。 随着该项目的成功完成,我们预计口服持久mRNA递送策略将提供 一种更有效和更强大的治疗血友病和其他出血性疾病的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xiangfei Han其他文献

Xiangfei Han的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Targeting the Amino Acid Transporter SLC7A5 for Pulmonary Fibrosis
靶向氨基酸转运蛋白 SLC7A5 治疗肺纤维化
  • 批准号:
    10630480
  • 财政年份:
    2023
  • 资助金额:
    $ 6.95万
  • 项目类别:
Determinants of amino acid transporter oligomerization in membranes
膜中氨基酸转运蛋白寡聚的决定因素
  • 批准号:
    10725968
  • 财政年份:
    2023
  • 资助金额:
    $ 6.95万
  • 项目类别:
Amino acid transporter SLC38A5 as a drug target for TNBC: Evaluation with genetic and pharmacologic approaches
氨基酸转运蛋白 SLC38A5 作为 TNBC 的药物靶点:用遗传和药理学方法进行评估
  • 批准号:
    10576760
  • 财政年份:
    2022
  • 资助金额:
    $ 6.95万
  • 项目类别:
Targeting the Amino Acid Transporter SLC7A5 for Treatment of Pulmonary Fibrosis
靶向氨基酸转运蛋白 SLC7A5 治疗肺纤维化
  • 批准号:
    10683793
  • 财政年份:
    2022
  • 资助金额:
    $ 6.95万
  • 项目类别:
Structural and functional elucidation of L-type amino acid transporter under lipid environment
脂质环境下L型氨基酸转运蛋白的结构和功能阐明
  • 批准号:
    21K15031
  • 财政年份:
    2021
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of new BNCT sensitizer based on molecular chirality recognition of amino acid transporter LAT
基于氨基酸转运蛋白LAT的分子手性识别开发新型BNCT敏化剂
  • 批准号:
    21K19348
  • 财政年份:
    2021
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Elucidation of tissue-repair response in lung fibrosis by focusing on the amino acid transporter SLC15A3
通过关注氨基酸转运蛋白 SLC15A3 阐明肺纤维化中的组织修复反应
  • 批准号:
    21K16155
  • 财政年份:
    2021
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Hybridized structure- and ligand- based drug discovery approaches targeting ASCT2, an amino acid transporter critical for upregulated cell proliferation in numerous cancer types
针对 ASCT2 的基于杂交结构和配体的药物发现方法,ASCT2 是一种氨基酸转运蛋白,对于多种癌症类型的细胞增殖上调至关重要
  • 批准号:
    10333203
  • 财政年份:
    2020
  • 资助金额:
    $ 6.95万
  • 项目类别:
Exploration of new therapeutic strategy targeting amino acid transporter in renal cell carcinoma
肾细胞癌靶向氨基酸转运蛋白治疗新策略的探索
  • 批准号:
    20K18108
  • 财政年份:
    2020
  • 资助金额:
    $ 6.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigating the Physiological Role of Cl- permeation through Excitatory Amino Acid Transporter 1 (
通过兴奋性氨基酸转运蛋白 1 研究氯渗透的生理作用(
  • 批准号:
    552252-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 6.95万
  • 项目类别:
    University Undergraduate Student Research Awards
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了